Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
03:48:32 EDT Wed 30 Apr 2025
Enter Symbol
or Name
USA
CA



Q:FBIO - FORTRESS BIOTECH INC - https://fortressbiotech.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
FBIO - Q1.41.40·1.790.51.75+0.074.2134.92114941.68  1.76  1.682.887  1.325Apr 29Apr 0115 min RT 2¢

Recent Trades - Last 10 of 494
Time ETExPriceChangeVolume
19:52:25Q1.720.0420
17:19:50Q1.730.05200
17:14:22Q1.73990.05991
16:49:00Q1.720.04200
16:37:39Q1.730.05500
16:36:32Q1.730.05300
16:34:39Q1.740.062
16:29:02Q1.730.05300
16:27:10Q1.730.055
16:27:10Q1.730.05295

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-04-01 16:01U:FBIONews ReleaseJourney Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer
2025-03-31 16:05U:FBIONews ReleaseFortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights
2025-03-28 08:30U:FBIONews ReleaseCheckpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates
2025-03-26 16:01U:FBIONews ReleaseJourney Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights
2025-03-24 08:30U:FBIONews ReleaseJourney Medical Corporation Launches Emrosi(TM) (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea
2025-03-19 16:02U:FBIONews ReleaseJourney Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025
2025-03-17 08:56U:FBIONews ReleasePartex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform
2025-03-12 08:31U:FBIONews ReleaseJourney Medical Corporation to Participate in the 37th Annual ROTH Conference
2025-03-09 22:06U:FBIONews ReleaseSun Pharma to Acquire Checkpoint Therapeutics
2025-03-05 16:15U:FBIONews ReleaseMustang Bio Regains Compliance with Nasdaq Capital Market Requirement
2025-03-05 16:01U:FBIONews ReleaseJourney Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi(TM) (DFD-29) to Treat Rosacea
2025-03-04 16:02U:FBIONews ReleaseJourney Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida
2025-02-27 16:05U:FBIONews ReleaseMustang Bio Announces Sale of Fixed Assets and Exit of Facility
2025-02-11 16:11U:FBIONews ReleaseMustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
2025-02-10 08:00U:FBIONews ReleaseMustang Bio Announces Closing of $8 Million Public Offering
2025-02-06 07:01U:FBIONews ReleaseMustang Bio Announces Pricing of $8 Million Public Offering
2025-01-27 08:31U:FBIONews ReleaseFortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT
2025-01-23 08:31U:FBIONews ReleaseJourney Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi(TM) (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea
2025-01-14 08:00U:FBIONews ReleaseMustang Bio Announces Reverse Stock Split
2025-01-06 08:00U:FBIONews ReleaseSentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes Disease